Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.
COVID
clinical pharmacology
infectious diseases
model-informed drug development
pandemic
pharmacometrics
repurposing
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
15
01
2021
received:
20
08
2020
accepted:
25
01
2021
pubmed:
4
2
2021
medline:
28
10
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential of a rapid treatment response via a repurposed drug (RD) while more targeted treatments are developed. Five steps of model-informed drug repurposing (MIDR) are discussed: (i) utilize RD product label and in vitro NP data to determine initial proof of potential, (ii) optimize potential posology using clinical pharmacokinetics (PK) considering both efficacy and safety, (iii) link events in the viral life cycle to RD PK, (iv) link RD PK to clinical and virologic outcomes, and optimize clinical trial design, and (v) assess RD treatment effects from trials using model-based meta-analysis. Activities which fall under these five steps are categorized into three stages: what can be accomplished prior to an NP emergence (preparatory stage), during the NP pandemic (responsive stage) and once the crisis has subsided (retrospective stage). MIDR allows for extraction of a greater amount of information from emerging data and integration of disparate data into actionable insight.
Identifiants
pubmed: 33534138
doi: 10.1111/bcp.14760
pmc: PMC8013376
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3388-3397Informations de copyright
© 2021 British Pharmacological Society.
Références
Res Synth Methods. 2020 May;11(3):443-456
pubmed: 32125077
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Gates Open Res. 2020 Jun 9;4:58
pubmed: 32656501
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Br J Clin Pharmacol. 2021 Sep;87(9):3425-3438
pubmed: 33373059
J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):431-43
pubmed: 24961742
Clin Pharmacol Ther. 2011 Dec;90(6):766-9
pubmed: 22089340
J Virol. 2011 Mar;85(6):2764-70
pubmed: 21191031
Antiviral Res. 2020 Jun;178:104805
pubmed: 32330482
Br J Clin Pharmacol. 2021 Mar;87(3):1589-1590
pubmed: 32779815
Br J Clin Pharmacol. 2021 Mar;87(3):707-711
pubmed: 32515023
N Engl J Med. 2015 Nov 19;373(21):2048-58
pubmed: 26580997
Stat Med. 2019 Jun 30;38(14):2505-2523
pubmed: 30895655
Infect Dis Ther. 2020 Sep;9(3):561-572
pubmed: 32740858
Br J Clin Pharmacol. 2021 Sep;87(9):3439-3450
pubmed: 32693436
Clin Infect Dis. 2020 Nov 19;71(16):2240-2242
pubmed: 32302000
Drug Discov Today. 2012 May;17(9-10):419-24
pubmed: 22227532
Clin Trials. 2020 Oct;17(5):472-482
pubmed: 32674594
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
Cancer Chemother Pharmacol. 2016 Mar;77(3):485-94
pubmed: 26758586
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514
pubmed: 32558354
J Infect Dis. 2011 Oct 1;204(7):996-1002
pubmed: 21881113
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
Nature. 2005 Sep 8;437(7056):209-14
pubmed: 16079797
Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594
pubmed: 28176362
J Virol. 2006 Aug;80(15):7590-9
pubmed: 16840338
Br J Clin Pharmacol. 2021 Sep;87(9):3388-3397
pubmed: 33534138
Lancet. 2000 May 27;355(9218):1845-50
pubmed: 10866439
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14
pubmed: 20622030